Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1991 1
1993 3
1994 1
1995 3
1996 1
1997 2
1998 6
1999 2
2000 4
2001 1
2002 3
2003 1
2004 2
2005 5
2006 7
2007 4
2008 9
2009 7
2010 8
2011 10
2012 11
2013 25
2014 19
2015 22
2016 25
2017 24
2018 37
2019 52
2020 61
2021 65
2022 74
2023 65
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

531 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ongoing qi
Search for Longning Qi instead (1 results)
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L. Qi C, et al. Nat Med. 2022 Jun;28(6):1189-1198. doi: 10.1038/s41591-022-01800-8. Epub 2022 May 9. Nat Med. 2022. PMID: 35534566 Free PMC article. Clinical Trial.
Claudin18.2 (CLDN18.2)-redirected CAR T cells showed promising efficacy against gastric cancer (GC) in a preclinical study. Here we report the interim analysis results of an ongoing, open-label, single-arm, phase 1 clinical trial of CLDN18.2-targeted CAR T cells (CT041) in …
Claudin18.2 (CLDN18.2)-redirected CAR T cells showed promising efficacy against gastric cancer (GC) in a preclinical study. Here we report t …
Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19.
Xu H, Li S, Liu J, Cheng J, Kang L, Li W, Zhong Y, Wei C, Fu L, Qi J, Zhang Y, You M, Zhou Z, Zhang C, Su H, Yao S, Zhou Z, Shi Y, Deng R, Lv Q, Li F, Qi F, Chen J, Zhang S, Ma X, Xu Z, Li S, Xu Y, Peng K, Shi Y, Jiang H, Gao GF, Huang L. Xu H, et al. Proc Natl Acad Sci U S A. 2023 May 2;120(18):e2301775120. doi: 10.1073/pnas.2301775120. Epub 2023 Apr 24. Proc Natl Acad Sci U S A. 2023. PMID: 37094153 Free PMC article.
The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global health concern, and effective antiviral reagents are urgently needed. ...
The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global health concern, and effective antiviral reagents are urgently n …
Transfer of Fresh versus Frozen Embryos in Ovulatory Women.
Shi Y, Sun Y, Hao C, Zhang H, Wei D, Zhang Y, Zhu Y, Deng X, Qi X, Li H, Ma X, Ren H, Wang Y, Zhang D, Wang B, Liu F, Wu Q, Wang Z, Bai H, Li Y, Zhou Y, Sun M, Liu H, Li J, Zhang L, Chen X, Zhang S, Sun X, Legro RS, Chen ZJ. Shi Y, et al. N Engl J Med. 2018 Jan 11;378(2):126-136. doi: 10.1056/NEJMoa1705334. N Engl J Med. 2018. PMID: 29320646 Free article. Clinical Trial.
There were also no significant between-group differences in the rates of implantation, clinical pregnancy, overall pregnancy loss, and ongoing pregnancy. Frozen-embryo transfer resulted in a significantly lower risk of the ovarian hyperstimulation syndrome than fresh-embry …
There were also no significant between-group differences in the rates of implantation, clinical pregnancy, overall pregnancy loss, and on …
Measuring Equity for Quality Improvement.
Menda N, Edwards E. Menda N, et al. Clin Perinatol. 2023 Jun;50(2):531-543. doi: 10.1016/j.clp.2023.01.010. Epub 2023 Mar 21. Clin Perinatol. 2023. PMID: 37201995 Review.
Applying an equity lens to quality improvement (QI) by collecting, reviewing, and using data that measure health disparities helps identify whether QI interventions improve outcomes evenly and equally across the population or have a greater impact in an advantaged o …
Applying an equity lens to quality improvement (QI) by collecting, reviewing, and using data that measure health disparities helps id …
A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2.
Chen J, Wang P, Yuan L, Zhang L, Zhang L, Zhao H, Chen C, Wang X, Han J, Chen Y, Jia J, Lu Z, Hong J, Lu Z, Wang Q, Chen R, Qi R, Ma J, Zhou M, Yu H, Zhuang C, Liu X, Han Q, Wang G, Su Y, Yuan Q, Cheng T, Wu T, Ye X, Zhang T, Li C, Zhang J, Zhu H, Chen Y, Chen H, Xia N. Chen J, et al. Sci Bull (Beijing). 2022 Jul 15;67(13):1372-1387. doi: 10.1016/j.scib.2022.05.018. Epub 2022 May 26. Sci Bull (Beijing). 2022. PMID: 35637645 Free PMC article.
Thus, this study demonstrates that the intranasally delivered dNS1-RBD vaccine candidate may offer an important addition to the fight against the ongoing coronavirus disease 2019 pandemic and influenza infection, compensating limitations of current intramuscular vaccines.. …
Thus, this study demonstrates that the intranasally delivered dNS1-RBD vaccine candidate may offer an important addition to the fight agains …
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Mateos MV, et al. Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23. Lancet Haematol. 2020. PMID: 32213342 Clinical Trial.
In this study (COLUMBA), we tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab. METHODS: In this ongoing, multicentre (147 sites in 18 countries), open-label, non-inferiority, randomised, phase 3 trial, we recruited adult patients (age 18 yea …
In this study (COLUMBA), we tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab. METHODS: In this ongoing …
Computational Design of Peptide Assemblies.
Min J, Rong X, Zhang J, Su R, Wang Y, Qi W. Min J, et al. J Chem Theory Comput. 2024 Jan 23;20(2):532-550. doi: 10.1021/acs.jctc.3c01054. Epub 2024 Jan 11. J Chem Theory Comput. 2024. PMID: 38206800 Review.
With the ongoing development of peptide self-assembling materials, there is growing interest in exploring novel functional peptide sequences. ...
With the ongoing development of peptide self-assembling materials, there is growing interest in exploring novel functional peptide se …
Developing future clinical leaders in patient safety: the Irish experience.
Murray K, Fitzgerald E, Ali A, Crosby D, O'Reilly S, Lachman P. Murray K, et al. BMJ Lead. 2023 Mar;7(1):9-11. doi: 10.1136/leader-2021-000462. Epub 2022 Aug 29. BMJ Lead. 2023. PMID: 37013882
This involves monthly group meetings with key patient safety opinion makers, one-on-one mentorship, leadership courses, conference attendance and presentations. Each scholar undertakes a quality improvement (QI) project. RESULTS: A QI project was associated with a d …
This involves monthly group meetings with key patient safety opinion makers, one-on-one mentorship, leadership courses, conference attendanc …
Application and development of noninvasive biomarkers for colorectal cancer screening: a systematic review.
Song D, Wang F, Ju Y, He Q, Sun T, Deng W, Ding R, Zhang C, Xu Q, Qi C, Bao J. Song D, et al. Int J Surg. 2023 Apr 1;109(4):925-935. doi: 10.1097/JS9.0000000000000260. Int J Surg. 2023. PMID: 36974713 Free PMC article.
Most studies reported optimistic findings based on preliminary research, and prospective clinical studies are ongoing. These promising biomarkers are expected to more accurately identify early-stage patients with CRC and be applied in the future....
Most studies reported optimistic findings based on preliminary research, and prospective clinical studies are ongoing. These promisin …
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade.
Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, Howe K, Bendinelli KJ, Qi H, Mo G, Montagne J, Leatherman JM, Lopez-Vidal TY, Zhu Q, Huff AL, Yuan X, Hernandez A, Coyne EM, Zaidi N, Zabransky DJ, Engle LL, Ogurtsova A, Baretti M, Laheru D, Durham JN, Wang H, Anders R, Jaffee EM, Fertig EJ, Yarchoan M. Shu DH, et al. bioRxiv [Preprint]. 2023 Oct 26:2023.10.16.562104. doi: 10.1101/2023.10.16.562104. bioRxiv. 2023. PMID: 37904980 Free PMC article. Preprint.
While TLS in viable tumor displayed a highly active mature morphology, in areas of tumor regression we identified an involuted TLS morphology, which was characterized by dispersion of the B cell follicle and persistence of a T cell zone enriched for ongoing antigen present …
While TLS in viable tumor displayed a highly active mature morphology, in areas of tumor regression we identified an involuted TLS morpholog …
531 results